Skip to search formSkip to main contentSkip to account menu

CEV regimen

Known as: Cytoxan-Etoposide-Vincristine Regimen, VEC regimen 
A regimen consisting of cyclophosphamide, etoposide and vincristine used for the treatment of extensive-stage small cell lung cancer.
National Institutes of Health

Related topics

Related topics

9 relations

Broader (4)

Antineoplastic Combined Chemotherapy ProtocolsCarboplatinEtoposidecisplatin/cyclophosphamide/etoposide protocol
CyclophosphamideParaplatinSmall cell carcinoma of lungVincristine

Narrower (1)

VEJ regimen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
PURPOSE Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and… 
Review
2016
Review
2016
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Many mammalian viruses have properties that can be commandeered for the treatment of cancer. These characteristics include… 
Highly Cited
2016
Highly Cited
2016
Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
9568Background: T-VEC is a herpes simplex virus (HSV)-1 -based oncolytic immunotherapy designed to selectively replicate in… 
Highly Cited
2015
Highly Cited
2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
PURPOSE Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively… 
Highly Cited
2015
Highly Cited
2015
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study of Pexa-Vec (pexastimogene… 
Highly Cited
2013
Highly Cited
2013
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in… 
Review
2013
Review
2013
Oncolytic viruses as therapeutic cancer vaccines
Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and associated… 
Review
2013
Review
2013
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage…
LBA9008 Background: T-VEC is an oncolytic immunotherapy (OI) derived from herpes simplex virus type-1 designed to selectively… 
Review
1995
Review
1995
Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
A total of 83 patients with nonorgan-confined bladder cancer with or without lymph node metastases (tumor stages pT3b, pT4a and… 
Highly Cited
1992
Highly Cited
1992
Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License